XNAS · Healthcare · Biotechnology
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.39 | -0.32 | +17.95% | $251,147 | ✅ Beat | +7.66% | +6.53% | — |
| 2026-03-16 | Q4 2025 | -0.21 | -0.34 | -61.90% | $4.0M | ❌ Miss | +0.22% | -6.22% | +0.67% |
| 2025-11-12 |
| Q3 2025 |
| -0.17 |
| -0.13 |
| +23.53% |
| $3.6M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.35 | -0.36 | -2.86% | $163,616 | ❌ Miss | -0.81% | -3.10% | +1.31% |
| 2025-03-18 | Q4 2024 | — | -0.18 | — | $2.0M | — | +0.00% | +1.55% | -18.45% |
| 2024-08-12 | Q2 2024 | -0.14 | -0.19 | -35.71% | $3.4M | ❌ Miss | -2.65% | +6.44% | +12.88% |
| 2024-03-19 | Q4 2023 | — | 0.15 | — | $6.0M | — | — | — | — |
| 2023-11-08 | Q3 2023 | — | -0.34 | — | $0 | — | -5.50% | -1.57% | +36.74% |
Showing last 8 quarters.